Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study
Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technologyKernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experienceCYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward…